Effect of elexacaftor/tezacaftor/ivacaftor on systemic inflammation in cystic fibrosis
{{output}}
Background: Despite significant clinical improvements, there is evidence of persisting airway inflammation in people with cystic fibrosis (CF) established on elexacaftor/tezacaftor/ivacaftor (ETI) therapy. As CF is a multi-system... ...
